Influence of cancer-related inflammation on plasma disposition of osimertinib in patients with non-small cell lung cancer using the Glasgow prognostic score.
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background: Osimertinib, an EGFR tyrosine kinase inhibitor, is mainly metabolized by CYP3A. This study investigated genetic and non-genetic factors influencing plasma osimertinib concentrations in 36 patients with non-small cell lung cancer. Changes in CYP3A activity were evaluated using its endogenous marker, 4β-hydroxycholesterol (4β-OHC).
Fields of Study & Subjects
Pharmacogenetics and Drug Metabolism
Lung Cancer Treatments and Mutations
Drug Transport and Resistance Mechanisms
Publication details
- Journal / source
- Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
- Volume
- 57
- Issue
- 2
- Pages
- 6–14
- Publication date
- 1 January 2026
- Language
- EN